Two high-ranking West Virginia state senators recently introduced a bipartisan bill that would prohibit drug manufacturer restrictions on 340B contract [...] …
Year: 2024
Drugmakers issued a record 41 refunds to 340B covered entities in 2023. And Merck is the first to announce it [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
In the complex landscape of healthcare, the 340B program plays a vital role in ensuring that vulnerable patients with limited financial resources have access to affordable medications. It enables qualified covered entities to maximize their resources and offer a wider range of benefits and services to those in need.
Managing this program efficiently and ensuring compliance with its myriad rules and regulations is a challenging task. This is where 340B consultants step in, serving as invaluable guides and experts. In this article, we will delve into the roles and responsibilities of a 340B consultant.
The Roles of a 340B Consultant
A 340B consultant is a professional who specializes in the 340B program. Their role is multifaceted and encompasses various responsibilities, all aimed at helping providers optimize the benefits of the program while maintaining compliance. Here’s a closer look at their roles:
- Program Assessment: One of the primary responsibilities of a 340B consultant is
Just days prior to implementing its first contract pharmacy restrictions, Japanese pharmaceutical giant Takeda yesterday announced it will increase the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) has announced plans to host a webinar for federal grantees just days prior [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Rhode Island state lawmakers last week introduced bills that would prohibit both differentiated payments from pharmacy benefit managers (PBMs) to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Influential state senators in Kentucky, Virginia, and Florida have introduced bills recently that would prohibit drug manufacturer restrictions on 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A senior Indiana state senator introduced a bill this week that would require 340B providers to annually report detailed financial [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Join our webinar for a comprehensive exploration of the current status of the 340B program, featuring a review of major industry trends from 2023 and key developments anticipated for 2024.
We’ll discuss what entities should expect and prepare for in the upcoming year, addressing crucial questions about manufacturer restrictions and potential Congressional actions.
Key Points from the 2023 Year in Review:
- Manufacturer Restrictions: A review of the past year’s events and their current impact on the 340B Program participants.
- HRSA’s Enhanced Authority: Notably, four entities were removed from the 340B Program, signaling a more assertive approach by HRSA.
- Leadership Change at OPA: We’ll examine the potential impact of the change in leadership at the Office of Pharmacy Affairs on the program.
Upcoming Challenges:
- Federal Appeals Court Opinions: Stay tuned for anticipated opinions from two federal appeals courts that could significantly impact the program.
- Genesis v. HRSA Patient Definition Battle: Explore
The nation’s leading hospital group warned the decision by federal regulators not to address 340B policy in a new proposed [...] …